Delta Financial Advisors LLC Has $1.40 Million Position in Abbott Laboratories $ABT

Delta Financial Advisors LLC decreased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 25.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,420 shares of the healthcare product maker’s stock after selling 5,223 shares during the period. Delta Financial Advisors LLC’s holdings in Abbott Laboratories were worth $1,399,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories during the fourth quarter valued at about $25,000. MidAtlantic Capital Management Inc. purchased a new position in Abbott Laboratories in the fourth quarter valued at about $25,000. Purpose Unlimited Inc. bought a new position in shares of Abbott Laboratories during the 4th quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $26,000. Finally, Abound Financial LLC purchased a new position in Abbott Laboratories in the fourth quarter valued at approximately $26,000. 75.18% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ABT shares. Citigroup increased their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. JPMorgan Chase & Co. raised their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. UBS Group lowered their target price on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $130.00 price target on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, Wells Fargo & Company boosted their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $119.50.

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $116.12 on Wednesday. The stock has a market cap of $200.94 billion, a price-to-earnings ratio of 37.58, a P/E/G ratio of 2.26 and a beta of 0.59. The stock’s 50-day moving average is $101.15 and its 200 day moving average is $100.09. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm’s revenue was up 13.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first continuous monitor designed to track both glucose and ketone levels. The device could strengthen Abbott’s FreeStyle Libre ecosystem, help identify rising ketones before diabetic ketoacidosis emergencies, and support compatibility with automated insulin-delivery systems. Reuters article
• Positive Sentiment: TD Cowen raised its price target for ABT to $135 from $115 and maintained a “buy” rating. The upgrade signals confidence in Abbott’s growth prospects, particularly in continuous glucose monitoring and medical devices. Benzinga article
• Positive Sentiment: Medtronic’s MiniMed Flex insulin pump has begun shipping with an Abbott-made glucose sensor, expanding the potential distribution and application of Abbott’s sensor technology in automated insulin delivery. MedTech Dive article
• Neutral Sentiment: Recent comparisons portray Abbott as a relatively attractive healthcare and continuous glucose monitoring investment, citing valuation, liquidity and price-target upside. These assessments may support sentiment but do not represent new company operating results. Yahoo Finance article
• Negative Sentiment: Abbott agreed to pay $670 million to settle claims that its specialized premature-infant formulas contributed to necrotizing enterocolitis. The settlement removes some litigation uncertainty but highlights continuing legal and financial risks. Insider Monkey article
• Negative Sentiment: Diagnostics growth remains uneven: strong routine testing and 13% cancer-diagnostics growth are being partly offset by weaker respiratory testing demand. This could temper near-term revenue momentum. Yahoo Finance article

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.